首页> 外文期刊>BMC Genomics >Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening
【24h】

Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

机译:通过全基因组CRISPR-Cas9缺失筛选鉴定致癌驱动基因突变

获取原文
           

摘要

Background Genome-wide CRISPR-Cas9 dropout screens can identify genes whose knockout affects cell viability. Recent CRISPR screens detected thousands of essential genes required for cellular survival and key cellular processes; however discovering novel lineage-specific genetic dependencies from the many hits still remains a challenge. Results To assess whether CRISPR-Cas9 dropout screens can help identify cancer dependencies, we screened two human cancer cell lines carrying known and distinct oncogenic mutations using a genome-wide sgRNA library. We found that the gRNA targeting the driver mutation EGFR was one of the highest-ranking candidates in the EGFR-mutant HCC-827 lung adenocarcinoma cell line. Likewise, sgRNAs for NRAS and MAP2K1 (MEK1), a downstream kinase of mutant NRAS, were identified among the top hits in the NRAS-mutant neuroblastoma cell line CHP-212. Depletion of these genes targeted by the sgRNAs strongly correlated with the sensitivity to specific kinase inhibitors of the EGFR or RAS pathway in cell viability assays. In addition, we describe other dependencies such as TBK1 in HCC-827 cells and TRIB2 in CHP-212 cells which merit further investigation. Conclusions We show that genome-wide CRISPR dropout screens are suitable for the identification of oncogenic drivers and other essential genes.
机译:背景全基因组CRISPR-Cas9缺失筛选可以鉴定其敲除影响细胞生存力的基因。最近的CRISPR筛选检测到了成千上万的细胞存活和关键细胞过程所需的必需基因。然而,从许多命中中发现新颖的谱系特异性遗传依赖性仍然是一个挑战。结果为了评估CRISPR-Cas9缺失筛查是否可以帮助识别癌症依赖性,我们使用了全基因组sgRNA文库筛选了两种携带已知和独特致癌突变的人类癌细胞系。我们发现靶向驱动基因突变EGFR的gRNA是EGFR突变HCC-827肺腺癌细胞系中排名最高的候选基因之一。同样,在NRAS突变的神经母细胞瘤细胞系CHP-212的最高命中位点中鉴定出了NRAS和MAP2K1(MEK1)的sgRNA(突变NRAS的下游激酶)。 sgRNA靶向的这些基因的消耗与细胞生存力测定中对EGFR或RAS途径的特定激酶抑制剂的敏感性高度相关。此外,我们描述了其他依赖性,例如HCC-827细胞中的TBK1和CHP-212细胞中的TRIB2,值得进一步研究。结论我们表明,全基因组CRISPR筛选技术适用于鉴定致癌驱动因子和其他必需基因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号